Purchase Order 75N93021P01402
- Not listed
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,460 firm fixed-price purchase order to Psomagen Inc. for COVID-19 RNA isolation, DNA generation, and library preparation services under the FY26 Unlisted Data Objective (UDO) Initiative. The contract, awarded on September 20, 2022, with an ultimate completion date of September 18, 2023, was performed at Psomagen's facility in Rockville, Maryland. No set-aside designation was applied to this procurement. Psomagen, a...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Psomagen Inc., a subsidiary of Macrogen, Inc. The $30,000 firm fixed-price purchase order was not set aside for any specific business type. Under this contract, Psomagen will provide a range of genomic and molecular biology services to support research across various NIH institutes, including the National Institute on Aging,...
- This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Psomagen Inc., a subsidiary of Macrogen, Inc. The $11,381 firm-fixed-price purchase order contract was awarded on July 5, 2011, with a completion date of July 4, 2012. The contract did not have a set-aside designation. Psomagen Inc. is a multiomics contract laboratory that provides a range of genomic and molecular biology services,...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Psomagen Inc., a subsidiary of Macrogen, Inc. The $10,000.00 firm fixed-price purchase order is for DNA sequencing services. The contract has no set-aside designation. Psomagen Inc. is a provider of genomic and molecular biology services, including whole genome sequencing, RNA sequencing, and epigenome sequencing, that supports...
- This federal contract award, valued at $44,940.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Psomagen Inc., a for-profit manufacturer of genomic sequencing and bioinformatics services. The contract is for "SEQUENCING NOVASEQX 25B 150PE, FLOW CELL" and has a firm fixed-price structure with a completion date of November 16, 2024. Psomagen Inc. is a subsidiary of Macrogen, Inc. and has...
- Psomagen Inc. has been awarded a purchase order from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases for library preparation, sequencing, and basic analysis services. The firm fixed price contract has a potential value of $14,000 and runs through April 13, 2024 with performance taking place in Bethesda, Maryland. Psomagen will leverage its CLIA certified and CAP accredited facilities to deliver genomic sequencing...
- This is a $206,250 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract is for total RNA sequencing services, with an option to increase the value. The awardee is Psomagen Inc., a for-profit manufacturer of genomics and molecular biology services based in Rockville, Maryland. This contract does not have a set-aside designation. Psomagen is...
- This federal contract award, valued at $4,380.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Psomagen Inc., a subsidiary of Macrogen, Inc. The contract is for a "Human & Herpes Virus mRNA Sequencing Project" in accordance with Psomagen's quote. The contract is a Firm Fixed Price purchase order with an ultimate completion date of August 28, 2014. Psomagen Inc. is not a small business, and the contract did not utilize a set-aside. Macrogen,...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Psomagen Inc. for $10,320.00 on September 15, 2022, for RNA extraction, DNA isolation, and library preparation services under the FY26 UDO Initiative. Work is performed in Rockville, Maryland. The order is firm fixed price with an ultimate completion date of October 14, 2022.</p>
- This is a firm-fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Psomagen Inc., a wholly-owned subsidiary of Macrogen, Inc. The contract ceiling value is $9,999.30 and it is for DNA sequencing services. The contract is not set aside for any specific business category. Psomagen Inc. is a leading provider of genomic and molecular biology services to federal agencies, including the National Institutes of Health (NIH), U.S. Department...
The National Institute of Allergy and Infectious Diseases awarded a $17,810 firm fixed price purchase order to Psomagen Inc. on September 13, 2021, with an ultimate completion date of August 4, 2022. This contract action was undertaken to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), in preparation for the September 30, 2026 closing of the period of availability for these fiscal year funds. The work was performed in Rockville, Maryland, where Psomagen maintains CLIA-certified and CAP-accredited facilities. No set-aside designation was applied to this contract award. Psomagen Inc., a subsidiary of Macrogen Inc., is a specialized provider of genomic sequencing and multi-omics data analysis services to federal agencies. The company's technical capabilities span whole genome sequencing, RNA sequencing, epigenome sequencing, and advanced bioinformatics support, services that align with the National Institute of Allergy and Infectious Diseases' research mission in infectious disease and immunology. Psomagen holds a substantial $500 million indefinite delivery vehicle with the National Heart, Lung, and Blood Institute for the Trans-Omics for Precision Medicine (TOPMed) initiative, demonstrating its established role as a key genomic services provider across the federal government.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00003 | Funding Only Action | ($2k) | 3/2/26 | |
| P00002 | Funding Only Action | ($40) | 12/12/25 | |
| P00001 | Other Administrative Action | $0 | 8/4/22 | |
| Not listed | Not listed | $20.0k | 9/13/21 |